1
|
Wei SY, Fu WS, Liu CH, Wang WL, Shih YT, Chien S, Chiu JJ. Identification of KU-55933 as an anti-atherosclerosis compound by using a hemodynamic-based high-throughput drug screening platform. Proc Natl Acad Sci U S A 2024; 121:e2318718121. [PMID: 38252820 PMCID: PMC10835076 DOI: 10.1073/pnas.2318718121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Accepted: 12/19/2023] [Indexed: 01/24/2024] Open
Abstract
Several compounds have been used for atherosclerosis treatment, including clinical trials; however, no anti-atherosclerotic drugs based on hemodynamic force-mediated atherogenesis have been discovered. Our previous studies demonstrated that "small mothers against decapentaplegic homolog 1/5" (Smad1/5) is a convergent signaling molecule for chemical [e.g., bone morphogenetic proteins (BMPs)] and mechanical (e.g., disturbed flow) stimulations and hence may serve as a promising hemodynamic-based target for anti-atherosclerosis drug development. The goal of this study was to develop a high-throughput screening (HTS) platform to identify potential compounds that can inhibit disturbed flow- and BMP-induced Smad1/5 activation and atherosclerosis. Through HTS using a Smad1/5 downstream target inhibitor of DNA binding 1 (Id-1) as a luciferase reporter, we demonstrated that KU-55933 and Apicidin suppressed Id-1 expression in AD-293 cells. KU-55933 (10 μM), Apicidin (10 μM), and the combination of half doses of each [1/2(K + A)] inhibited disturbed flow- and BMP4-induced Smad1/5 activation in human vascular endothelial cells (ECs). KU-55933, Apicidin, and 1/2(K + A) treatments caused 50.6%, 47.4%, and 73.3% inhibitions of EC proliferation induced by disturbed flow, respectively, whereas EC inflammation was only suppressed by KU-55933 and 1/2(K + A), but not Apicidin alone. Administrations of KU-55933 and 1/2(K + A) to apolipoprotein E-deficient mice inhibited Smad1/5 activation in ECs in athero-susceptible regions, thereby suppressing endothelial proliferation and inflammation, with the attenuation of atherosclerotic lesions in these mice. A unique drug screening platform has been developed to demonstrate that KU-55933 and its combination with Apicidin are promising therapeutic compounds for atherosclerosis based on hemodynamic considerations.
Collapse
Affiliation(s)
- Shu-Yi Wei
- Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli350, Taiwan
| | - Wei-Shan Fu
- Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli350, Taiwan
| | - Chang-Hsuan Liu
- Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli350, Taiwan
| | - Wei-Li Wang
- Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli350, Taiwan
| | - Yu-Tsung Shih
- Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli350, Taiwan
- Department of Anatomy and Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei110, Taiwan
| | - Shu Chien
- Department of Bioengineering and Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA93093
- Department of Medicine, University of California, San Diego, La Jolla, CA93093
| | - Jeng-Jiann Chiu
- Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli350, Taiwan
- College of Medical Science and Technology, Taipei Medical University, Taipei110, Taiwan
- Taipei Heart Institute, Taipei Medical University, Taipei110, Taiwan
- Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu300, Taiwan
| |
Collapse
|
2
|
Pascual I, Moris C, Avanzas P. Beta-Blockers and Calcium Channel Blockers: First Line Agents. Cardiovasc Drugs Ther 2016; 30:357-365. [DOI: 10.1007/s10557-016-6682-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
4
|
References. Med J Aust 2000. [DOI: 10.5694/j.1326-5377.2000.tb139429.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Abstract
The spasm of resistance vessel (S-RV) concept of ischemic diseases avers that S-RV representing vascular autoregulatory dysfunction directly induces symptoms in ischemic diseases. The most important ischemic diseases, ischemic heart disease (IHD) and stroke, generally are not attributed to S-RV, and new evidence will be provided in this communication that S-RV induces IHD and stroke. Hypertension and the ischemic disorders of migraine and Raynaud's disease have been attributed to S-RV and to vascular dysregulation, and this information was used to help structure the study. It was found that these disorders are closely associated with IHD and stroke, and this is consistent with S-RV and vascular dysregulation as the mechanism for IHD and stroke. Also, it was found that multiple risk factors for IHD foster S-RV and are risk factors for hypertension, migraine, Raynaud's disease, and stroke, and this supports S-RV as the mechanism for IHD and stroke.
Collapse
Affiliation(s)
- H R Hellstrom
- Department of Pathology, Health Science Center at Syracuse, State University of New York, 13210, USA.
| |
Collapse
|
7
|
Hjemdahl P, Eriksson SV, Held C, Rehnqvist N. Prognosis of patients with stable angina pectoris on antianginal drug therapy. Am J Cardiol 1996; 77:6D-15D. [PMID: 8677897 DOI: 10.1016/s0002-9149(96)00301-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Antianginal drug treatment reduces symptoms and ischemia but may also influence the prognosis of patients with stable angina pectoris. The Atenolol Silent Ischemia Study (ASIST) compared atenolol and placebo treatment (about 140 patient-years on each) in patients with mainly silent ischemia and found less aggravation of angina and a tendency toward fewer cardiac complications with atenolol treatment. The Total Ischaemic Burden European Trial (TIBET) compared slow release nifedipine, atenolol, or the combination (about 450 patient-years on each) and found no significant differences with regard to cardiac complications, a nonsignificant trend toward better prognosis on combined treatment, and more side effects on nifedipine alone compared with the other treatments. The Angina Prognosis Study in Stockholm (APSIS) compared metoprolol and verapamil (about 1,400 patient-years on each) and found similar effects on cardiovascular endpoints, tolerability, and psychosocial variables with the 2 treatments. Hypothesis-generating subgroup analyses in APSIS suggest that treatment effects may differ in hypertensive and diabetic subgroups. Beneficial effects in primary and secondary prevention, together with data from ASIST, suggest that beta 1 blockade influences prognosis favorably. The safety of short-acting nifedipine in ischemic heart disease is questioned, but TIBET data suggest that slow release nifedipine may be safe. Verapamil has beneficial effects after myocardial infarction (Danish Verapamil Infarction Trial II) and shows similar efficacy as metoprolol in the APSIS study. The paucity of placebo data (antianginal treatment cannot be withheld during long periods of time in symptomatic patients) precludes firm conclusions regarding effects of drug treatment on prognosis. It is argued that patients with stable angina pectoris do well on medical treatment, and that beta 1 blockers, verapamil, and, possibly, slow-release nifedipine may influence their prognosis favorably.
Collapse
Affiliation(s)
- P Hjemdahl
- Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden
| | | | | | | |
Collapse
|